Small molecule · Degrader of BRAF · developed by Fore Biotherapeutics
Early Phase 1Most advanced trial
What is Plixorafenib?
Plixorafenib is an orally bioavailable BRAF inhibitor that acts as a dimer breaker, binding dimeric BRAF mutants, including BRAF fusions and splice variants, as well as BRAFV600 monomers. It is being studied in BRAF V600E-mutated tumors.
Summary written with AI from the sources listed at the end of this page.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.